28 Feb Flash Note : Annual Financial Results 2023 – Significant Sales and EBITDA Growth – Outperformance against Target Sales
Posted at 15:17h
in 2024, Announcements, Announcements 2024, Consolidated Financial Results, Consolidated Financial Results 2023, Results 2024
Flash Note : Annual Financial Results 2023
(Unaudited Financial Data)
Paiania, February 28, 2024 – Lavipharm S.A. informs the investment community on the key financial figures for the fiscal year 2023 and the Group’s operational developments:
Consolidated Sales from ongoing operations, excluding Rebate & Clawback, amounted to EUR 57.43 in 2023, compared to EUR 45.14 mio in 2022, presenting a 27.2% increase. Moreover, consolidated Sales from ongoing operations, excluding Rebate & Clawback, exceeded the management’s adjusted target of EUR 52.27 mio by 9.8%. Notably, the 2023 and 2022 Sales were adjusted due to the cessation of wholesale operations and logistics services to third parties (3PL) in February 2024.